Indivumed GmbH (Indivumed) and Helomics Corporation (Helomics) announce their intentions to collaborate to analyze human cancer biospecimens and annotated clinical data from consenting patients around the world, enabling cutting-edge basic and translational research in cancer.
“Attaining individualized cancer diagnosis and treatment for every patient based on reliable clinical data and molecularly intact biospecimens is our goal,” said Hartmut Juhl, M.D., Founder and CEO of Indivumed, and a cancer researcher. “Our tool for achieving this goal is the establishment of a unique global cancer database using molecular information from tissues collected under stringent protocols and offering cutting-edge research capabilities in our laboratories in Germany. Helomics brings a special blend of research analytics expertise, CLIA service capabilities, and proprietary research platforms that will complement our existing research infrastructure, allowing for the most advanced development of cancer biomarkers, driving the next generation of precision medicine for cancer.”
Gerald J. Vardzel Jr., President and CEO of Helomics stated, “The combination of Helomics, a recognized leader in oncology for personalized medicine diagnostic assay development and commercialization and Indivumed, a global leader in the capture, curation and analysis of molecular and clinical cancer data, and biospecimens, provides a unique opportunity for tissue-based diagnostic development and validation spanning the preclinical to clinical research pipeline.”
This partnership will allow customers of both companies to benefit from a joint offering of Indivumed’s leading cancer database, biobank and world-class research laboratory in Europe and Helomics’ leading proprietary analytical laboratory services for biospecimen analysis in the US together with a broad range of CLIA testing capabilities and cutting-edge bioinformatics platform.
The terms and conditions of the collaborative agreement were not disclosed.
